Gilead Sciences. has filed a patent for antibodies that bind to HIV gp120 and neutralize the virus, along with methods for using these antibodies to treat or prevent HIV infection. Claim 1-67 has been canceled. GlobalData’s report on Gilead Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Gilead Sciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Gilead Sciences, Peptide pharmacophores was a key innovation area identified from patents. Gilead Sciences's grant share as of January 2024 was 44%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding to hiv gp120 for treating hiv infection

Source: United States Patent and Trademark Office (USPTO). Credit: Gilead Sciences Inc

A patent application (Publication Number: US20240034774A1) has been filed for an antibody or antigen-binding fragment that binds to the human immunodeficiency virus-1 (HIV-1) Envelope glycoprotein gp120. The antibody comprises specific sequences in the heavy chain variable region (VH) and light chain variable region (VL), with defined glycosylation sites that are sialylated. The patent also covers a pharmaceutical composition containing the antibody and a host cell expressing the antibody, emphasizing the sialylation of N-linked glycosylation sites in the variable domains of the expressed antibodies.

Furthermore, the patent application includes a method of inhibiting HIV in a human subject by administering the antibody or antigen-binding fragment. The amino acid sequences of the heavy chain variable region (VH) and light chain variable region (VL) are specified, with an emphasis on sialylation at specific sites. The patent application highlights the potential therapeutic use of the antibody in combating HIV and the importance of glycosylation patterns in enhancing its efficacy.

To know more about GlobalData’s detailed insights on Gilead Sciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies